Advertisement


Farhad Ravandi, MD, on AML: Highlights of Ongoing Research

SOHO 2025

Advertisement

Farhad Ravandi, MD, provides an overview of acute myeloid leukemia (AML) research highlighted in a session at SOHO, including data on menin inhibitors in NPM1-mutated disease; FLT3 inhibitors in FLT3-mutated disease; IDH inhibitors in IDH1-mutated disease; the role of measurable residual disease; what’s on the horizon for immunotherapy; risk stratification; and a discussion of the use of lower-intensity regimens. 



Related Videos

Leukemia

Elias Jabbour, MD, on CAR T-Cell Therapy for Adult Patients With Relapsed/Refractory B-Cell ALL

Elias Jabbour, MD, discusses long-term findings and predictors of sustained remission among adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) who did not undergo a stem cell transplant, but received the chimeric antigen receptor (CAR) T-cell therapy obecabtagene autoleucel. 

Advertisement

Advertisement




Advertisement